Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication

Predictive Biomarkers for Bevacizumab: Are We There Yet?

(2013) D. Maru et al.   CLINICAL CANCER RESEARCH

Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581

(2013) Alan P. Venook et al.   JOURNAL OF CLINICAL ONCOLOGY

HOXB9 Expression Promoting Tumor Cell Proliferation and Angiogenesis Is Associated with Clinical Outcomes in Breast Cancer Patients

(2012) Hirohito Seki et al.   ANNALS OF SURGICAL ONCOLOGY

Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

(2012) D. O. Bates et al.   CLINICAL CANCER RESEARCH

Homeodomain-containing protein HOXB9 regulates expression of growth and angiogenic factors, facilitates tumor growth in vitro and is overexpressed in breast cancer tissue

(2012) Bishakha Shrestha et al.   FEBS Journal

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

(2010) A. Bagri et al.   CLINICAL CANCER RESEARCH

Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

(2009) J. P.B. O'Connor et al.   CLINICAL CANCER RESEARCH

HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis

(2009) T. Hayashida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA